Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 16/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878683 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1878685 | 1.00 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL12637115 | 0.92 | CFTR (0.84) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL8002983 | 0.90 | CFTR (0.82) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1327044 | 0.90 | CFTR (0.82) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1882015 | 0.89 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1325936 | 0.89 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1882013 | 0.89 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1881090 | 0.88 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A | |
| SCHEMBL1881092 | 0.88 | CFTR (1.00) | CFTRNLRP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058295-B2 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100130571-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-27 | — | — | US | disclosed |
| US-7638543-B2 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | US | disclosed |
| US-7235573-B2 | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1549321-A4 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1549321-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| WO-2004028480-A2 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130571-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20080064666-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20040235800-A1 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | CFTR, TMEM205, TMEM33 | CFTR 1/4885NLRP3 444/4885MEN1 4413/4885 |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, PKD1, PKD2 | CFTR 1/4885NLRP3 852/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.